Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Guardat en:
Autors principals: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Idioma: | anglès |
Publicat: |
Philipps-Universität Marburg
2023
|
Matèries: | |
Accés en línia: | PDF a text complet |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
No abstracts were found for this record.